Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 4/2015

Open Access 01-12-2015 | Original Research

Randomized Questionnaire Based Case–Control Research Study on Evaluation of Sexual Function in Indian Patients Taking Oral Finasteride for Androgenetic Alopecia

Author: C.R.V. Narasimhalu

Published in: Dermatology and Therapy | Issue 4/2015

Login to get access

Abstract

Introduction

Finasteride is one of the most common drugs used in androgenetic alopecia. The literature discusses the sexual side effects of the drug; however, in practice there is little evidence to support this. The aim of the present study was to investigate the sexual dysfunction in patients taking finasteride 1 mg for androgenetic alopecia.

Methods

A questionnaire, based on the International Index of Erectile Function, was given to approximately 586 patients with androgenetic alopecia who were being treated with finasteride 1 mg for an average of 16 weeks. These patients were compared to an age-related control group who were attending the Dermatology Out Patients Department for various other skin ailments not related to hair disorders.

Results

Statistical analysis of the results showed no significant difference in the scores between patients taking finasteride and the control group.

Conclusion

Analysis showed no significant difference in sex-related problems with that of patients taking finasteride and age matched controls, suggesting that sex-related issues are not a side effect of finasteride.
Appendix
Available only for authorised users
Literature
1.
Roberts JL, Fielder V, Imperato-McGinley J, et al. Clinical dose ranging studies with Finasteride, a type 2 5 alpha reductase. J Am Acad Dermatol. 1999;40:930–7.CrossRef
2.
Kaufman KD, Olsean EA, Whiting D, et al. Finasteride in the treatment of man with androgenetic alopecia. J Am Acad Dermatol. 1998;39:578–9.CrossRefPubMed
3.
Brenner S, Matz H. Improvement in androgenic alopecia in 53–76 years old men using oral Finasteride. Int J Dermatol. 1999;38:928–30.CrossRefPubMed
4.
Arndt KA, Hsu JTS. Manual of dermatologic therapeutics. 7th ed. Lippincott Williams & Wilkins; p. 339–40.
5.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF) a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.CrossRefPubMed
6.
Kligman AM. The comparative histopathology of male pattern baldness and senescent baldness. In: De Villez RL, editor. Clinics in dermatology. Philadelphia: Lippincot; 1998. p. 108–13.
7.
Hoffmann R, Van Neste D. Recent findings with computerized methods for scalp hair growth measurements. J Invest Dermatol Symp Proc. 2005;10:285–8.CrossRef
8.
RG Valia, Valia AR, editors. IADVL textbook of dermatology, vol 1. 3rd ed. p. 894.
9.
Hamilton JB. Male hormone stimulation is prerequisite and an incitement in common baldness. Am J Anat. 1942;71:451–60.CrossRef
10.
Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40:930–7.CrossRefPubMed
11.
Tosti A, Piraccini BM, Soli M. Evaluvation of sexual function in subjects taking finasteride for the treatment of androgenic alopecia. J Eur Acad Dermatol Venereol. 2001;15:418–21.PubMed
Metadata
Title
Randomized Questionnaire Based Case–Control Research Study on Evaluation of Sexual Function in Indian Patients Taking Oral Finasteride for Androgenetic Alopecia
Author
C.R.V. Narasimhalu
Publication date
01-12-2015
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 4/2015
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-015-0084-3

Other articles of this Issue 4/2015

Dermatology and Therapy 4/2015 Go to the issue

Brief Report

An Applicator Delivery System for Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Topical Suspension (Gel): Innovating Psoriasis Vulgaris Treatment Through Patient Collaboration

Case Report

Imiquimod 5% as Adjuvant Therapy for Incompletely Excised Infiltrative Nodular Basal Cell Carcinoma and Dermoscopy to Monitor Treatment Response

Case Report

Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses

Original Research

Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients’ Quality of Life: a Prospective, Non-interventional Trial

Brief Report

A Novel Topical 2% Povidone–Iodine Solution for the Treatment of Common Warts: A Randomized, Double-Blind, Vehicle-Controlled Trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits